These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24686773)

  • 21. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
    Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent androgen deprivation: clinical experience and practical applications.
    Wright JL; Higano CS; Lin DW
    Urol Clin North Am; 2006 May; 33(2):167-79, vi. PubMed ID: 16631455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight.
    Tunn U
    BJU Int; 2007 Jan; 99 Suppl 1():19-22; discussion 23-4. PubMed ID: 17229164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding heterogeneity of treatment effect in prostate cancer.
    Aly A; Mullins CD; Hussain A
    Curr Opin Oncol; 2015 May; 27(3):209-16. PubMed ID: 25689354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.
    Hird AE; Magee DE; Bhindi B; Ye XY; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z; Wallis CJD
    Clin Genitourin Cancer; 2020 Oct; 18(5):343-350. PubMed ID: 32278840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intermittent androgen deprivation (IAD) for advanced prostate cancer. Why not the standard of therapy?].
    Prapotnich D; Sánchez-Salas R; Cathelineau X; Stakhovskyi O; Rocha JE; Vallancien G
    Arch Esp Urol; 2009 Nov; 62(9):689-94. PubMed ID: 19955592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Metastatic hormone-sensitive prostate cancer: more than just androgen-deprivation therapy].
    Mechahougui H; Achard V; Friedlaender A
    Rev Med Suisse; 2020 May; 16(695):1098-1101. PubMed ID: 32462838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Quality of life in patients diagnosed of prostate cancer treated with continuous androgen deprivation therapy vs. intermittent therapy].
    Sierra Labarta CR; Sánchez Zalabardo D; de Pablo Cárdenas A
    An Sist Sanit Navar; 2015; 38(2):193-201. PubMed ID: 26486525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials.
    Ramos-Esquivel A; Fernández C; Zeledón Z
    Urol Oncol; 2016 Aug; 34(8):335.e9-335.e19. PubMed ID: 27052629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    BJU Int; 2015 Jul; 116(1):30-6. PubMed ID: 25523493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery.
    Sciarra A; Cattarino S; Gentilucci A; Alfarone A; Innocenzi M; Gentile V; Salciccia S
    Urol Oncol; 2013 Jul; 31(5):607-14. PubMed ID: 21665494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Value of intermittent androgen deprivation in the context of the current data situation].
    Miller K; Hammerer P; Eichenauer R; Geiges G; Lehmann J; Rodemer G; Ruessel C; Rulf W; Suttmann H; Wolff JM
    Aktuelle Urol; 2013 Jul; 44(4):271-6. PubMed ID: 23888406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.